No Data
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
No Data
No Data
